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infusion etc.). In measuring the number of tests conducted and time per test, i.e. labo-
ratory efﬁ ciency, we found that the use of regadenoson versus adenosine and dipyri-
damole could reduce the overall test time by 18 and 17 minutes respectively. Assuming
a baseline of 39 pharm-stress MPI tests per week for both adenosine and dipyridamole, 
the time saved per test using regadenoson translates into potentially servicing addi-
tional 330–366 patients per year. CONCLUSIONS: Due to its weight-independent
calculation and its administration via a rapid injection, the use of regadenoson may 
result in direct savings of laboratory personnel time and labor and the potential for 
increased patient throughput versus adenosine or dipyridamole. These time savings 
could lead to increased laboratory efﬁ ciencies (scheduling additional tests per week or 
reorganizing staff more efﬁ ciently).
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PREDICTED REDUCTION IN HOSPITAL DAYS AND ASSOCIATED COSTS
AMONG MANAGED CARE PRIMARY AND SECONDARY RISK MIXED
DYSLIPIDEMIA PATIENTS TREATED WITH FIXED DOSE NIACIN
EXTENDED-RELEASE AND SIMVASTATIN COMBINATION THERAPY
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OBJECTIVES: Compare predicted incremental reduction in hospital days and associ-
ated costs in managed health care (MHC) mixed dyslipidemia patient cohort treated 
with ﬁ xed-dose niacin extended-release and simvastatin (NERS) therapy. METHODS:
Two hypothetical formularies were modeled, a baseline formulary which did not 
include NERS and an adjusted formulary which did. Other lipid therapies included 
all marketed branded medications. The model was developed using product labeling,
clinical trial results, national prescription claims data, and a risk equation derived
from the HealthCore Integrated Research Database to estimate the incidence of car-
diovascular disease (CVD) events and associated hospital days avoided among patients 
achieving and not achieving optimal lipid values for LDL-C, HDL-C, and triglycerides 
(TG). Study patients included those aged q18 years with sub-optimal baseline LDL-C 
q 100 mg/dL, HDL-C a 40 mg/dL for males; a 50 mg/dL for females, and/or TG
levels q 150 mg/dL for females/diabetics; q 200 mg/dL for males/non-diabetics. A 
cost-effectiveness analysis was performed over three years evaluating the incremental
cost per hospital-day avoided after addition of NERS to current formulary. RESULTS:
Among 1,000,000 patients, 529,620 primary and secondary risk patients (52.96%) 
aged q 18 years were identiﬁ ed. Mean age at baseline was 54 o 11 years and 45%
was female. Over 3 years, there was reduction of 157 hospital days after addition
of NERS versus current formulary (54,839 vs. 54,997 days) along with a reduction
of $4,888,916 in total costs (sum of health plan costs, copayment, drug-monitoring 
costs, and CVD-event related costs) [$1,337,787,345 vs. $1,342,676,261], thus
achieving an incremental cost-saving of $31,041 per hospital day avoided. CONCLU-
SIONS: The MHC database-based model predicts that treating sub-optimal HDL-C 
and TG beyond achievement of optimal LDL-C goals may result in health care 
resource savings to a MHC organization after the addition of NERS to a managed
care formulary.
CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes Studies
PCV75
IMPACT OF MEDICATION ADHERENCE ON CARDIOVASCULAR
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OBJECTIVES: Assess the impact of optimal medication adherence on total cardiovas-
cular disease (CVD)-related total health care cost (THC) among dyslipidemia patients 
initiating ﬁ xed dose combination (FDC) therapy versus multi-pill combination (MPC) 
therapies in a managed care setting. METHODS: Study patients q 18 years were
identiﬁ ed as newly-initiating on FDC [Advicor: niacin extended release (NER) 
lovastatin] or MPC’s [simvastatin  NER (NER/S), lovastatin  NER (NER/L)] 
between January 1, 2000-June 30, 2006 [index date], with a minimum 6 months pre- 
and 12 months post-index health plan eligibility from a managed care database.
Multivariate generalized linear model was used to estimate association between opti-
mally adherent patients [Medication possession ratio (MPR) q 80%] and one-year
post-index CVD-related THC [sum of emergency room, inpatient, outpatient, and
medication costs] and sub-optimally adherent patients (MPR  80%) after controlling
for key demographic (age, gender) and clinical variables (FDC and MPC cohorts, 
comorbidity burden and number of non-dylipidemia medications). RESULTS: A total 
of 8988 patients (6638 FDC; 1687 NER/S; 663 NER/L) were identiﬁ ed. Those initiat-
ing FDC therapy were signiﬁ cantly younger [mean (SD) ages of 51.9 (10.5) vs. 56.0 
(9.8) years, p  0.0001] and had signiﬁ cantly lower baseline Deyo-Charlson comorbid-
ity scores (0.43 o 0.88 vs. 0.59 o 1.06; p  0.0001) versus MPC patients. At one year 
post-index, average MPR was higher among FDC patients versus both NER/S and
NER/L patients (0.54 o 0.35 vs. 0.50 o 0.35 and 0.47 o 0.34, respectively; p  0.01). 
After controlling for differences in baseline variables, multivariate regression showed
that patients with optimal adherence (MPR q 80%) had a 40% decrease in annual 
CVD-related THC versus sub-optimally adherent patients [Estimate: 0.601, 95% CI: 
0.427 – 0.845); p  0.003]. CONCLUSIONS: Optimal medication adherence among 
dyslipidemia managed care patients showed reduced CVD-related THC versus patients 
showing sub-optimal adherence. Further studies on early initiation of FDC therapy
targeting residual risk in dyslipidemia patients are warranted.
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OBJECTIVES: The purpose of this study was to test the theoretical model of whether 
patient’s efﬁ cacy expectations and outcome expectations mediate the relationship 
between health literacy and medication adherence. In addition, the relationships 
between patients’ demographic variables and their health literacy skills, outcome 
expectations, efﬁ cacy expectations and medication adherence were evaluated
METHODS: A survey composed of four validated instruments along with questions
related to patient’s demographic information was utilized. The four validated instru-
ments assessed functional health literacy (S-TOFHLA), medication related outcome 
expectations and efﬁ cacy expectations and medication adherence (MARS). The 
questionnaire was pretested by conducting a pilot study of 21 patients with hyperten-
sion at a community health clinic. RESULTS: In the main study 200 patients with 
hypertension completed the self-administered survey. Path analysis was used to test
the theoretical model. Age had statistically signiﬁ cant associations with health literacy 
scores (ñ  0.17, p  0.015), efﬁ cacy expectations (ñ  0.23, p  0.004), and medica-
tion adherence (ñ  0.27, p  0.0001). In addition, number of prescriptions taken 
daily and insurance (t  5.30, p  0.001) had a statistically signiﬁ cant association
with medication adherence (ñ  0.16, p  0.024). Health literacy was only variable
that was statistically correlated with income (ñ  0.21, p  0.003) and level of educa-
tion (ñ  0.29, p  0.001). Path analysis indicated that medication adherence was sig-
niﬁ cantly associated with age and efﬁ cacy expectations, which also was related to 
health literacy level, age and income. Health literacy was also a signiﬁ cant predictor 
of outcome expectations. Gender, level of education, and income were the only demo-
graphic variables signiﬁ cantly associated with health literacy scores. CONCLUSIONS:
The results of the study suggested that health literacy had an impact on medication
adherence through efﬁ cacy expectations.
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OBJECTIVES: Poor adherence to antihypertensive therapy increases patient risks 
of cardiovascular events. The objective of this study was to measure the effectiveness
of an individualized educational program on medication adherence and blood
pressure (BP) control. METHODS: This was a six-month, longitudinal study with a 
prospectively identiﬁ ed intervention group and a retrospective control group. The
Scott & White Health Plan enrollment and claim databases and EMR were utilized 
to identify continuously enrolled patients aged 18 years or older, diagnosed with 
hypertension, and treated with valsartan, aliskiren, or a ﬁ xed-dose combination of 
valsartan/hydrochlorothiazide or amlodipine/valsartan for at least three months 
prior to study enrollment. Patients meeting the inclusion criteria were invited to 
participate in the prospective intervention arm of the study, while those with geo-
graphic limitation served as controls. The intervention group received monthly per-
sonalized information about hypertension and treatment. A power analysis determined 
150 participants would be required in each arm to detect a 3% change in MPR. The 
intervention and control groups were matched based on demographic characteristics 
and Charlson Comorbidity Index score. All interval data were analyzed using paired 
t-tests, while categorical data were analyzed using chi-square tests. RESULTS: A
total of 159 patients enrolled into the study (60% female; mean [SD] age, 62 [12.6] 
years). Analysis of 95 matched patients showed no signiﬁ cant mean (SD) change in 
MPR (86% [0.2] to 83% [0.25] vs. 85% [0.24] to 82% [0.29]; P  0.8), systolic BP
(137.2 [15.1] to 136.3 [15] vs. 132.2 [14.8] to 136 [16.4] mmHg; P  0.2) and diastolic 
BP (72.6 [9.8] to 73.7 [13.1] vs. 72 [10.2] to 70.8 [10.5] mmHg; P  0.5) for the
intervention and control groups, respectively. CONCLUSIONS: Our pre liminary 
analysis showed no signiﬁ cant change in medication adherence and blood pressure. A 
complete analysis is necessary to determine the impact of the educational tool.
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OBJECTIVES: The objective of this systematic review was to evaluate the impact of 
interventions to improve medication compliance in patients on antihypertensive medi-
cations. METHODS: CINAHL, EMBASE, all EBM Reviews and MEDLINE electronic
databases were searched for articles published January 1979 through February 2007
using MeSH keywords relevant to patient compliance and intervention type, yielding
